Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Receivables (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Receivables for 16 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 111.08% year-over-year to $5.3 million, compared with a TTM value of $5.3 million through Oct 2025, up 111.08%, and an annual FY2025 reading of $5.3 million, up 111.08% over the prior year.
  • Receivables was $5.3 million for Q4 2025 at Pharma-Bio Serv, up from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $10.4 million in Q2 2021 and bottomed at $572000.0 in Q4 2021.
  • Average Receivables over 5 years is $5.0 million, with a median of $5.0 million recorded in 2022.
  • The sharpest move saw Receivables tumbled 94.12% in 2021, then skyrocketed 771.07% in 2022.
  • Year by year, Receivables stood at $572000.0 in 2021, then skyrocketed by 771.07% to $5.0 million in 2022, then fell by 20.91% to $3.9 million in 2023, then plummeted by 36.29% to $2.5 million in 2024, then skyrocketed by 111.08% to $5.3 million in 2025.
  • Business Quant data shows Receivables for PBSV at $5.3 million in Q4 2025, $2.0 million in Q3 2025, and $5.3 million in Q2 2025.